NF2 and meningioma: However, rapid clinical translation by repurposing FDA/NICE approved drugs such as bosutinib, sorafenib, mitoxantrone, and nintedanib (which are yet to be clinically assessed in VS or meningioma) in combination with immunotherapies may offer a dual benefit to NF2-SWN patients presenting with both meningioma and VS.